An investor post lists the planned lineup, from sermorelin and NAD+ to BPC-157, with Hims now taking email signups ahead of launch.
Recap by typeshit. Post by Riyado Sofian on X.
CNBC's investing team lifts its target on Lilly shares and argues the obesity drug run still has room to grow.
The Pharma Letter looks at how semaglutide generics are changing strategy in India, with Torrent eyeing an expansion into Brazil.
Semafor looks at how little national political figures have said about what the new class of weight loss drugs means for policy.
The doctors take on two of the topics their followers ask about most, giving their verdict on statins and Ozempic.
Social media promoters claim peptides speed healing, smooth skin and extend life, and CBS notes the HHS Secretary counts himself a fan.
A Dongguk University family medicine professor calls gallbladder risk the real concern and says some Koreans fly to Japan, where the drugs reportedly cost about a third.
Loading…